Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov ID: NCT07915791

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07915791. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

ALARMONY: A Phase 2 Randomized, Double Blind, Placebo Controlled Multi-center Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe COPD

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is for adult participants with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who continue to experience exacerbations despite standard of care triple therapy treatment. It will assess the effectiveness and safety of two investigational drugs, GSK3862995B and GSK5784283, given together compared to a placebo in addition to standard of care.

Study identification

NCT ID
NCT07915791
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
279 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 29, 2026 (Actual)
Primary completion
Mar 7, 2029 (Estimated)
Completion
Feb 6, 2030 (Estimated)
Last update posted
Nov 17, 2026

2026 – 2030

United States locations

U.S. sites
8
U.S. states
8
U.S. cities
8
Facility City State ZIP Site status
GSK Investigational Site Newport Beach California 92663 Recruiting
GSK Investigational Site Miami Florida 33176-7016 Recruiting
GSK Investigational Site Derby Kansas 67037 Recruiting
GSK Investigational Site Columbia Maryland 21045 Recruiting
GSK Investigational Site Oklahoma City Oklahoma 73111 Recruiting
GSK Investigational Site Philadelphia Pennsylvania 19107 Recruiting
GSK Investigational Site Rock Hill South Carolina 29732 Recruiting
GSK Investigational Site Tomball Texas 77375 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07915791, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 17, 2026 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.